Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Return on Equity (2022 - 2025)

InMed Pharmaceuticals' Return on Equity history spans 4 years, with the latest figure at 0.72% for Q4 2025.

  • For Q4 2025, Return on Equity rose 36.0% year-over-year to 0.72%; the TTM value through Dec 2025 reached 0.72%, up 36.0%, while the annual FY2025 figure was 0.72%, 0.0% changed from the prior year.
  • Return on Equity reached 0.72% in Q4 2025 per INM's latest filing, down from 0.66% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.51% in Q1 2024 to a low of 5.55% in Q3 2023.
  • Average Return on Equity over 4 years is 1.53%, with a median of 1.08% recorded in 2024.
  • Peak YoY movement for Return on Equity: plummeted -364bps in 2023, then surged 477bps in 2024.
  • A 4-year view of Return on Equity shows it stood at 1.34% in 2022, then plummeted by -197bps to 3.97% in 2023, then skyrocketed by 73bps to 1.08% in 2024, then surged by 33bps to 0.72% in 2025.
  • Per Business Quant, the three most recent readings for INM's Return on Equity are 0.72% (Q4 2025), 0.66% (Q3 2025), and 0.8% (Q2 2025).